Microbot Medical Inc. (MBOT) · Nov 5, 2026 · Other events
Canadian patent granted — 45 issued patents; 48 applications worldwide
Microbot Medical’s patent filing strengthens LIBERTY’s protection, but offers no immediate change to regulatory progress, adoption, or revenue.
Microbot is in the early commercialization phase of LIBERTY, expanding U.S. hospital adoption while building sales coverage and pursuing international regulatory clearance; management recently targeted a CE Mark in late Q4 2026 or early Q1 2027.
The filing strengthens an existing moat, rather than changing the operating story. CIPO granted protection for an adaptor connecting guidewires or microcatheters to a motorized robotic surgical device. 〔0〕 The addition takes Microbot to 45 issued patents and 48 applications worldwide, including 21 issued patents in North America. 〔1〕
The practical impact is limited today. The patent may help protect LIBERTY’s design and support future international expansion, but it does not itself add a regulatory clearance, customer, order, revenue, or manufacturing improvement. Patent-building was already a visible part of the company’s strategy, including a multiple-patent announcement on October 20, 2026, so this is incremental confirmation rather than a new commercial inflection.
Bottom line: This is modestly helpful IP progress for a company trying to commercialize LIBERTY, but it does not materially advance the near-term sales or regulatory milestones that define the story now.
CE Mark decision expected late Q4 2026 or early Q1 2027
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!